<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962923</url>
  </required_header>
  <id_info>
    <org_study_id>NJGLYY003</org_study_id>
    <nct_id>NCT00962923</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore safety and efficacy of allogeneic mesenchymal stem cells
      transplantation (MSCT) to treat patients with diagnosis of systemic sclerosis(SSc) who have
      been resistant to multiple standard treatments. The underlying hypothesis is that the SSc
      condition is caused by an abnormal immune homeostasis that can be restored by MSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To test a new approach using allogeneic derived mesenchymal stem cell based therapy
           (MSCT) to treat refractory SSc

        -  To determine the disease-free survival in SSc patients treated with MSCT

        -  To assess adverse events of allogeneic MSC transplantation

        -  To assess the association of remission for organ function, clinical score and SSc
           serology levels at baseline with disease-free survival
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mRSS score,HRQOL score, SF-36 score for SSc patients</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission for organ function, VC, DLCO, PAP, serum albumin, serum creatitin, weight loss, 24h proteinuria</measure>
    <time_frame>every three month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSc Serology(ATA,ACA,ANA,anti-ssDNA,anti-dsDNA,IgM,IgG,and IgA,complement C3 and C4</measure>
    <time_frame>every three month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of peripheral blood B and T cells</measure>
    <time_frame>every three month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells (AlloMSC)</intervention_name>
    <description>Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients fulfilled the American College of Rheumatology (former American
             Rheumatism Association - ARA) for SSc

          -  Rapidly progressive disease &lt;2 years duration with a modified Rodnan skin score(mRSS)
             above 20, plus ESR &gt;25 mm/first h and/or Hb &lt;11 g/dL, not explained by other causes
             than active SSc

          -  lung involvement: with a vital capacity (VC) or DLCO below 70% predicted, or a mean
             pulmonary artery pressure (PAP) above 40 mmHg (measured by echocardiography)

          -  digestive tract involvement: with serum albumin ,25 g/L or weight loss exceeding 10%
             body weight in the preceding year

          -  kidney involvement: with 24-h urinary protein above 0.5 g or serum creatinine above
             120 mmol/L

        Exclusion Criteria:

          -  Uncontrolled arrhythmia, echocardiographic left ventricular ejection fraction (LVEF)
             &lt;50% or mean PAP &gt;50 mmHg, DLCO&lt;45% of predicted

          -  Creatinine clearance &lt;20 ml/min

          -  Platelets&lt;80 000/mm3, haemorrhagic cystitis

          -  (4) HIV or HTLV1 seropositivity, malignancy, pregnancy, a cardiac or vascular
             prosthesis, and no vascular access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lingyun Sun, MD</last_name>
    <phone>+86-25-83105219</phone>
    <email>lingyunsun2001@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Affiliated Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yitao Ding, MD</last_name>
      <phone>+86-25-83106666</phone>
      <phone_ext>66866</phone_ext>
      <email>yitaoding@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009 Jun;27(6):1421-32. doi: 10.1002/stem.68.</citation>
    <PMID>19489103</PMID>
  </reference>
  <reference>
    <citation>Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, Sun L. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. 2009 May;15(5):644-6. doi: 10.1177/1352458509104590.</citation>
    <PMID>19389752</PMID>
  </reference>
  <reference>
    <citation>Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008 Dec;5(6):417-24. doi: 10.1038/cmi.2008.52.</citation>
    <PMID>19118507</PMID>
  </reference>
  <reference>
    <citation>Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121-8.</citation>
    <PMID>17402368</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <last_update_submitted>August 19, 2009</last_update_submitted>
  <last_update_submitted_qc>August 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name_title>
    <organization>the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</organization>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

